Collegium Pharma Also Gets A "Pass"
Oct 9, 2024
Collegium Pharmaceutical (COLL) develops and markets medicines for pain management, focused largely on extended release formulations of addictive opioid-based drugs. Currently, the firm sells 3 drugs, each contributing about 30% of revenue. Xtampza ER is an extended release version of oxycodone. Nucynta ER is a similar formulation of tapentadol, another powerful opioid. Belbuca is a form of buprenorphine, a synthetic opioid that can also be highly addictive. I have a few concerns with investing in this one. First, after the recent purchase of Ironshore to add ADHD drug Journay ER, Collegium will have a substantial amount of debt and only about a 2x interest coverage ratio (that's risky). Second, there is board room drama, with former CEO Joe Ciaffoni forced out in May by founder Michael Heffernan. And finally, about 1/3rd of current sales are at risk in the next few years as Nucynta goes off-patent. Just too many issues with this one. I'm passing on adding it to the Watch List.
Follow @GreenDotStocks
Information contained on this website represents only the opinions of the author and should not be used as the sole basis for investing decisions. By using this site, you agree to all statements in the Site Policy.
Watch List
| APPF | 4.30% |
| CMG | 40.33% |
| PSTG | -1.39% |
| WDAY | -5.41% |
| VEEV | 19.23% |
| INTU | 20.20% |
| RDDT | 16.57% |
| NTNX | 27.22% |
| CRWD | 95.83% |
| SE | 32.72% |
| SNOW | 13.92% |
vs. Fair Value Estimates
Buy List
| PINS | -38.24% |
| SEMR | -33.68% |
| TSM | -40.25% |
| ZETA | -27.44% |
| GOOG | -50.34% |
| NYAX | -30.24% |
| MSFT | -28.00% |
| FLYW | -39.29% |
| HRMY | -59.63% |
| YOU | -39.80% |
| ABNB | -31.51% |
| ADBE | -41.68% |
vs. Fair Value Estimates
Hold List
| ASML | -23.91% |
| VTEX | -13.76% |
| ODD | -6.91% |
| ASR | -24.09% |
| CELH | 39.84% |
| TOST | 18.60% |
| CPNG | -11.81% |
| HIMS | -5.43% |
| PAYC | -18.56% |
| MNDY | 21.64% |
| GLBE | -21.93% |
| ZS | 38.75% |
| V | -4.82% |
| ADSK | 1.57% |
| NOW | 15.34% |
| MELI | -19.68% |
| FTNT | 1.73% |
| TEAM | 0.14% |
vs. Fair Value Estimates